Asthma Inhaler Device Market Key Player Growth Analysis Like GlaxoSmithKline Plc., Merck & Co., Inc., 3M, Aristopharma Ltd., SRS PHARMACEUTICALS PVT. LTD., Intas Pharmaceuticals, Ltd. Etc. Forecast to 2022

Global Asthma Inhaler Device Market - Key Players

Some of the key players in this market are

GlaxoSmithKline Plc. (U.K)
Merck & Co., Inc. (US)
3M (US)
Aristopharma Ltd. (Bangladesh)
SRS PHARMACEUTICALS PVT. LTD. (India)
Intas Pharmaceuticals, Ltd. (India)

Global Asthma Inhaler Device Market - Segmentation

The Global Asthma Inhaler Device Market is divided into device type, technology, and end-user.

Based on device type, the market is segmented into metered-dose inhaler, MDI with a spacer, dry-powder inhaler, and others.

Based on technology, the market is segmented into manually operated inhaler devices and digitally operated inhaler devices.

Based on end-user, the market is segmented into hospital, clinics, research institutes, and others.

Global Asthma Inhaler Device Market – Overview

The Global Asthma Inhaler Devices Market is likely to expand at 5.2 % CAGR during the forecast period (2017-2022) owing to the increasing prevalence of asthma among the crowd, asserts Market Research Future (MRFR). An inflammatory disease of the lungs, asthma is characterized by the difficulty faced while breathing. The symptoms of asthma are often triggered with exposure to allergens such as ragweed, pollen, animal dander, and irritants such as chemical fumes and smoke. Asthma leads to swelling of the inside walls of an asthmatic’s airways and makes airways sensitive to irritations.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1653

Industry News:

September 3, 2018: The National Institute for Health and Care Excellence has recently approved a new procedure called bronchial thermoplasty, which is offered to the adults suffering from severe asthma. The procedure has been proven to be safe and can reduce the frequency and severity of attacks.

May 2018, a new asthma device which requires less force to activate has been created by engineers at the University of Cape Town. Named Easy Squeeze, the device is an assistant device for metered-dose asthma inhalers and is easier for children and elderly patient.

In May 2018, SmartAir, a Northern Ireland based health equipment manufacturer, developed a sensor technology named Airbrio, which aids patients to improve their inhalation technique and provides a compliance score.

Feb 2017 BI received expantion of FDA approval of the use of Tiotropium Respimat for treatment of Asthma in Children. With this approval, company will be able to sell the product inside the United States.

Jan 2017 AstraZeneca announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. Symbicort is approved in the US to treat asthma in patients 12 years and older and for the maintenance and treatment of COPD in adults, the company is expecting larger market share with the product launch.

Nov 2016 Chiesi acquires Atopix therapeutics. The acquisition of the UK based clinical stage biotechnology company will help Chiesi enhance its Asthma Segment.

Feb 2015 AstraZeneca and Actavis Plc have entered into a definitive agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above certain revenue threshold.

Global Asthma Inhaler Device Market - Regional Analysis

Depending on geographic region, Globally North America is the largest market for Asthma Inhalers. Currently there are around 6.4% of American suffering from COPD in U.S. and around 5.4 million people suffering from asthma in U.K. This major growth is attributed to the popularity of the dry powder inhalers among population due to its several advantages over Metered Dose Inhalers and other types of inhalers.

Europe is the second-largest market for asthma inhalers. It is observed that almost 70% of the child’s death occurred per year due to respiratory disorders are due to these sudden attacks hence rescue medication or rescue inhalers can serve better to save lots of lives per year.

Browse Complete 80 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/asthma-inhaler-device-market-1653

Asia pacific region is expected to be fastest growing region in respiratory Inhaler market. Middle East & Africa is expected to have limited but steady growth in the market. These countries with the advancement of technology are expected to show large number of cases of asthma and other respiratory disease which remain unnoticed currently.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.